{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NEOVADE","nct_id":"NCT06300424","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neovade-nct06300424. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"NEOVADE","arms":[{"description":"6 weeks of almonertinib followed by 3 cycles of neoadjuvant adebrelimab (1200mg every 3 weeks) with nab-paclitaxel and carboplatin (nab-paclitaxel 135 mg/m2, d1 and d8, and carboplatin AUC 5, d1 every 3 weeks) will be administered before surgery, followed by optional adjuvant treatment including EGFR-TKIs up to 3 years or immunotherapy for up to 1 year or till disease progression or unacceptable toxicity.","label":"Almonertinib and Chemo-immunotherapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-04-30","type":"ESTIMATED"},"conditions":["Non Small Cell Lung Cancer","EGFR Gene Mutation"],"enrollment":{"count":32,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"almonertinib","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Nab paclitaxel","type":"DRUG"}],"last_update":"2026-04-29","lead_sponsor":"Guangdong Provincial People's Hospital","official_title":"Neoadjuvant Almonertinib Followed by Adebrelimab-based Chemo-immunotherapy in II-IIIB EGFR-mutant Non-small Cell Lung Cancer, a Single Arm, Phase II Study","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-01-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Major Pathological Response (MPR)","timeFrame":"MPR will be assessed within 2 weeks after surgery"}],"references":[],"start_date":{"date":"2024-04-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC","url":"https://clinicaltrials.gov/study/NCT06300424"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neovade-nct06300424"}